DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• DexCom, Inc. (NASDAQ:DXCM) has received a consensus rating of “Moderate Buy” from analysts, with four hold ratings, fifteen buy ratings, and three strong buy ratings based on coverage from twenty-two brokerages.
• The average price target set by analysts for DexCom is $99.89, with recent target adjustments up to $106.00 by firms like UBS Group and Canaccord Genuity.
• In its latest earnings report, DexCom reported $0.48 earnings per share, exceeding expectations and marking a 15.2% revenue increase year-over-year, with revenues for the quarter totaling $1.16 billion.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-two brokerages that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $99.8947.

Several equities analysts have recently weighed in on the stock. Raymond James Financial lifted their target price on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Mizuho upped their price target on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. UBS Group increased their target price on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Oppenheimer raised their price target on DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $106.00 price target on shares of DexCom in a report on Friday, August 1st.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $81.67 on Thursday. The firm has a 50 day moving average of $82.85 and a 200-day moving average of $79.97. The stock has a market capitalization of $32.03 billion, a PE ratio of 56.72, a PEG ratio of 1.70 and a beta of 1.43. DexCom has a 12 month low of $57.52 and a 12 month high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts predict that DexCom will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director directly owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,906 shares of company stock worth $2,675,251. 0.32% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently bought and sold shares of DXCM. Andra AP fonden acquired a new stake in DexCom during the second quarter worth about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in DexCom in the second quarter worth approximately $26,000. Golden State Wealth Management LLC lifted its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in DexCom during the 1st quarter valued at $27,000. Finally, Optiver Holding B.V. acquired a new position in shares of DexCom in the fourth quarter worth $33,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.